Disease Biology

2:55
Prognostic drivers in AML and MDS
Ilaria Iacobucci
3:33
The MAGIC algorithm probability: a novel response biomarker for acute GvHD
Hrishikesh Srinagesh et al.
1:04
T-cell bispecific antibody targeting intracellular WT1 in AML
Marion Subklewe
2:30
Impact of gut mycobiota on outcomes after allo-HSCT
Mohamad Mohty
1:48
Fecal microbiota transfer for steroid refractory acute GvHD
Mohamad Mohty
1:17
Predictors of early relapse in transplant-eligible MM patients
Francesca Gay
1:21
Evaluation of systemic immunity in cHL via single cell cytokine secretion technology
Catherine Diefenbach
6:22
Integrated sequencing in AML/MDS reveals prognostic constellations
Ilaria Iacobucci
2:13
Lymphoma tumor microenvironment influences toxicity after CD19 CAR-T
Michael Jain
3:38
Novel HCK inhibitor has a synergistic effect with azacytidine or cytarabine in AML cells
Sara Olalla Saad
1:58
Mutational profiling reveals subset of R/R AML that may benefit from quizartinib
Mark Levis
7:02
BCL11A as therapeutic target in SCD: gene therapy trial
David Williams
1:56
Molecular profile of MPN with SVT significantly impacts prognosis
Jean-Jacques Kiladjian
1:36
Integrated sequencing utilized in a timely and impactful manner in AML/MDS
Charles Mullighan
1:48
Genomic landscape of childhood ALL: new analysis delves deeper than ever
Charles Mullighan
1:37
Emerging mutations at relapse in FLT3-mutated R/R AML on gilteritinib
Mark Levis
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals